CoreCap Advisors’s Anixa Biosciences ANIX Stock Holding History

CoreCap Advisors’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$146K	Hold	52,020	–	–	﹤0.01%	977
2026 Q1	$134K	Buy	52,020 +3,985	+8%	+$11.8K	﹤0.01%	932
2025 Q4	$150K	Buy	48,035 +1,248	+3%	+$5.11K	0.01%	887
2025 Q3	$154K	Hold	46,787	–	–	0.01%	877
2025 Q2	$154K	Buy	46,787 +2,000	+4%	+$5.71K	0.01%	837
2025 Q1	$128K	Hold	44,787	–	–	0.01%	817
2024 Q4	$104K	Hold	44,787	–	–	﹤0.01%	916
2024 Q3	$141K	Sell	44,787 -2,107	-4%	-$6.48K	0.01%	795
2024 Q2	$104K	Buy	46,894 +2,600	+6%	+$7.37K	0.01%	489
2024 Q1	$138K	Buy	+44,294	New	+$177K	0.01%	735
2022 Q4	$154K	Sell	36,209 -1,177	-3%	-$5.66K	0.01%	596
2022 Q3	$184K	Buy	37,386 +250	+0.7%	+$1.01K	0.02%	492
2022 Q2	$114K	Sell	37,136 -480	-1%	-$1.51K	0.01%	648
2022 Q1	$103K	Buy	37,616 +2,664	+8%	+$7.82K	0.01%	535
2021 Q4	$104K	Buy	+34,952	New	+$141K	0.01%	730

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

CoreCap Advisors's ANIX Position: Q2 2026 in Review

CoreCap Advisors held its Anixa Biosciences (ANIX) position steady in Q2 2026 at 52,020 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #977.

CoreCap Advisors first reported a position in ANIX in Q4 2021 and has held it in 15 quarters since. The position peaked at $184K in Q3 2022. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

CoreCap Advisors held 52,020 shares of Anixa Biosciences worth $146K as of Q2 2026.
CoreCap Advisors left its Anixa Biosciences share count unchanged in Q2 2026.
Anixa Biosciences made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #977 holding.
CoreCap Advisors first reported a position in Anixa Biosciences in Q4 2021 and has held it in 15 quarters since.
CoreCap Advisors's Anixa Biosciences position peaked at $184K in Q3 2022.
62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.